Article info
PDFClinical science
Type 3 neovascularisation (retinal angiomatous proliferation) treated with antivascular endothelial growth factor: real-world outcomes at 24 months
- Correspondence to Dr Alessandro Invernizzi, Eye Clinic, Department of Biomedical and Clinical Science “Luigi Sacco”, Luigi Sacco Hospital, University of Milan, Milan 20157, Italy; alessandro.invernizzi{at}gmail.com
Citation
Type 3 neovascularisation (retinal angiomatous proliferation) treated with antivascular endothelial growth factor: real-world outcomes at 24 months
Publication history
- Received July 25, 2018
- Revised October 17, 2018
- Accepted November 5, 2018
- First published December 1, 2018.
Online issue publication
August 23, 2019
Article Versions
- Previous version (23 August 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.